Surface treatment agent and surface treatment method of corneal contact lens
By using the ring-opening reaction product of acrylate copolymer and aminosilane coupling agent as the surface treatment agent, the problems of low adsorption efficiency and poor stability of proteins on the surface of corneal contact lenses are solved, and more efficient anti-protein adsorption performance and longer service life.
Patent Information
- Application Number
- CN202411219930.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has problems of low efficiency and poor stability in reducing the adsorption of proteins and oils on the surface of corneal contact lenses. In particular, the adsorption of proteins by polysiloxane is particularly serious, affecting the oxygen permeability and service life of the lens.
The ring-opening reaction product of acrylate copolymer and aminosilane coupling agent is used as the surface treatment agent. By introducing maleic anhydride monomer and aminosilane coupling agent, an amide structure is formed to improve the uniformity of trialkoxy silicon groups. Distribution and reactivity enhance anti-protein adsorption performance.
It significantly improves the anti-protein adsorption performance and stability of corneal contact lenses, avoids the negative impact of polysiloxane structure on protein adsorption, extends the service life of the lens and reduces the sense of foreign matter.
Smart Images

Figure BDA0005022723790000021 
Figure BDA0005022723790000051 
Figure BDA0005022723790000111
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of surface treatment, and relates to a surface treatment agent and a surface treatment method for a corneal contact lens. Background Art
[0002] Wearing corneal contact lenses (such as contact lenses, cosmetic lenses, etc.) has become a daily behavior for many people. The tears secreted by the human eye contain components such as proteins and oils, which are easily adhered to the surface of the corneal contact lens, forming a layer of protein precipitation of uneven thickness and affecting the performance of the lens, such as poor oxygen permeability, shortened life, etc., and will also cause the wearer to have aggravated foreign body sensation, occasional discomfort, and even allergies. In particular, corneal contact lenses containing polysiloxane are more susceptible to protein adsorption. In the prior art, there are generally two methods for treating such protein precipitation. The first method is to covalently bond and graft a thin layer of anti-protein adhesion material on the surface of the corneal contact lens to reduce the adhesion of proteins, oils, etc.; the second method is to add a protein removal component to the care solution, and the adhered proteins, oils, etc. will be removed after the corneal contact lens is immersed in the care solution.
[0003] For the above method (1), the prior art records a method of covalently grafting a cholyl phosphate-containing polymer or a cholyl phosphate-containing low molecular weight compound on the surface of a corneal contact lens, which can reduce protein adsorption and inhibit oil adhesion. For this method, the covalent bonding grafting efficiency and the grafting structure are the most important factors determining the anti-protein adsorption performance. The higher the grafting efficiency, the more grafted cholyl phosphate-containing polymers or low molecular weight cholyl phosphate compounds, the better the anti-protein adsorption performance, the more stable the grafting structure, and the more durable the anti-protein adsorption.
[0004] Therefore, the above-mentioned prior art needs to be further improved and perfected. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a surface treatment agent and a surface treatment method for a corneal contact lens.
[0006] The technical solution of the present invention is as follows:
[0007] A surface treatment agent is a ring-opening reaction product of an acrylate copolymer and an aminosilane coupling agent, wherein the acrylate copolymer is copolymerized by the following comonomers: (A) 5-85% by weight of phosphorylcholine-containing (methyl) acrylate, (B) 10-90% by weight of alkyl acrylate, and (C) 1-5% by weight of maleic anhydride.
[0008] Preferably, the structure of the aminosilane coupling agent is as shown in the following formula (1):
[0009] NH2R1Si(OR2)3(1)
[0010] Among them, R1 is C2-C8 alkylene or C3-C8 oxygen, sulfur, nitrogen substituted alkylene, and R2 is C1-C4 alkyl.
[0011] Preferably, the structure of the phosphorylcholine-containing (meth)acrylate is as shown in the following formula (2):
[0012]
[0013] Wherein, R3 is selected from H or C1-C4 alkyl, R4 is one or a combination of polyethoxy and polypropoxy with a degree of polymerization of 1-10 or C1-C10 alkylene, R5, R6 and R7 are independently selected from C1-C8 alkyl, and a=1-10.
[0014] Preferably, the structure of the alkyl acrylate is as shown in the following formula (3):
[0015] CH2=C(R8)COOR9 (3)
[0016] Wherein, R8 is selected from H or C1-C4 alkyl, and R9 is selected from C1-C8 alkyl.
[0017] Preferably, the carboxyl group generated by the ring-opening reaction product of the acrylate copolymer and the aminosilane coupling agent reacts with the aminosilane coupling agent to form an amide structure.
[0018] Preferably, the carboxyl group generated by the ring-opening reaction product of the acrylic ester copolymer and the aminosilane coupling agent reacts with the amine alkyl group to form an amide structure.
[0019] The structure of the aminoalkyl group is shown in the following formula (4):
[0020] NH2R 10 (4)
[0021] Where R 10 Selected from C1-C10 alkyl or C2-C10 oxygen, sulfur or nitrogen substituted alkyl.
[0022] A method for treating the surface of a corneal contact lens comprises using a treatment liquid containing a surface treatment agent described in any of the above technical solutions to perform surface treatment.
[0023] Preferably, the corneal contact lens is pre-treated with plasma before the surface treatment.
[0024] Preferably, the concentration of the surface treatment agent in the treatment solution is 0.01-1 wt %.
[0025] Preferably, the treatment liquid further contains a surfactant.
[0026] The beneficial effects of the present invention are:
[0027] (1) The surface treatment agent of the present invention contains a phosphorylcholine-containing (meth)acrylate (MPC) monomer, so the surface treatment agent has good biocompatibility and anti-protein adsorption performance. By introducing maleic anhydride monomer into the surface treatment agent and reacting with an aminosilane coupling agent, the side chain trialkoxysilyl group is relatively long from the main chain, which avoids the trialkoxysilyl group being coated by the main chain or other side chains, resulting in lower activity. Therefore, the surface treatment agent of the present invention has a high reaction activity with substrates (such as contact lenses, etc.).
[0028] (2) Maleic anhydride monomer is used. Maleic anhydride monomer cannot be homopolymerized, so the distribution of maleic anhydride in the copolymer structure is relatively uniform, which makes the distribution of trialkoxysilyl groups in the surface treatment agent relatively uniform, avoiding the competition between adjacent trialkoxysilyl groups and the substrate in the reaction. The reaction between the trialkoxysilyl groups and the substrate is more balanced and complete, the bonding force between the surface treatment agent and the substrate is higher, and the enhanced protein adsorption caused by the fact that some trialkoxysilyl groups do not participate in the reaction to form polysiloxane is avoided.
[0029] (3) After the corneal contact lens is pre-treated with plasma, there are more hydroxyl groups, carboxyl groups, etc. distributed on the surface, which can react with the trialkoxysilyl groups in the surface treatment agent, so that the surface treatment agent can be chemically bonded and grafted to the surface of the contact lens, thereby improving the hydrophilicity and anti-protein adsorption properties of the contact lens. DETAILED DESCRIPTION
[0030] The technical solution of the present invention is further illustrated and described below through specific implementation methods.
[0031] In the prior art, in order to graft phosphorylcholine-containing acrylate monomers onto the surface of corneal contact lenses, usually a monomer containing unsaturated carbon-carbon double bonds (such as vinyl trimethoxysilane) is first grafted onto the surface of the corneal contact lens, and then solution polymerization is performed, and the remaining monomers are grafted onto the surface of the lens by copolymerization. However, in this method, the monomers are easily self-polymerized in the solution, and the grafting situation is also uncontrollable. In order to improve the grafting effect of the surface treatment agent containing phosphorylcholine, on the one hand, the present invention provides a surface treatment agent, the surface treatment agent is a ring-opening reaction product of an acrylate copolymer and an aminosilane coupling agent, and the acrylate copolymer is copolymerized by the following copolymer monomers: (A) 5-85% by weight of phosphorylcholine-containing (meth) acrylate, (B) 10-90% by weight of alkyl acrylate, and (C) 1-5% by weight of maleic anhydride.
[0032] Copolymers of phosphorylcholine (meth)acrylate and alkyl acrylate have been applied to the anti-protein adsorption treatment of contact lenses. In order to graft the copolymers of phosphorylcholine (meth)acrylate onto contact lenses, it is necessary to introduce functional groups that can react with the surface of the lenses into the copolymer structure. In the prior art, polymerizable silane coupling agent monomers such as vinyltrimethoxysilane and 3-allyloxypropyltrimethoxysilane are generally added during polymerization, but these polymerizable silane coupling agent monomers are prone to form multiple adjacent or similar structures on the polymer main chain, resulting in the following problems: (1) There is a competitive relationship between multiple adjacent alkoxysilyl groups and the lens substrate when reacting, and some alkoxysilyl groups cannot fully react; (2) Unreacted alkoxysilyl groups will hydrolyze and condense to form polysiloxane structures, which have good adsorption properties to proteins and affect the anti-protein effect. A small amount of maleic anhydride monomer is added to the acrylate copolymer of the present invention. Maleic anhydride cannot be homopolymerized under conventional polymerization conditions, and the polymerization rate of maleic anhydride is lower than that of comonomer (A) and comonomer (B), so adjacent or close maleic anhydride structures will not be formed in the acrylate copolymer of the present invention, and the distribution of maleic anhydride in the polymer is relatively balanced, and then the ring-opening reaction of aminosilane coupling agent and maleic anhydride is introduced, while the trialkoxysilyl group that can be grafted is introduced, the trialkoxysilyl group will not form multiple adjacent or close structures. Therefore, in the surface treatment agent of the present invention, the distribution of the trialkoxysilyl group is relatively balanced, and a higher grafting efficiency and a more complete reaction can be achieved, which helps to improve the anti-protein adsorption performance of the surface treatment agent.
[0033] In the present invention, the preparation method of the acrylate copolymer can adopt a free radical polymerization method, such as a solution polymerization method, using an azo free radical initiator (such as AIBN) as an initiator, and anhydrous ethanol, DMF, DMAc, DMSO, etc. as a solvent. After the solution polymerization reaction is completed, the solution can be put into a large amount of ether for precipitation, and the precipitate can be collected and dried to obtain.
[0034] Furthermore, in the comonomer of the above-mentioned acrylate copolymer, the weight percentage of phosphorylcholine-containing (meth)acrylate is not less than 50%. For example, it can be any value among 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, etc., but is not limited to the above-mentioned values.
[0035] In the above technical solution, the structure of the aminosilane coupling agent is shown in the following formula (1):
[0036] NH2R1Si(OR2)3(1)
[0037] Among them, R1 is C2-C8 alkylene or C3-C8 oxygen, sulfur, nitrogen substituted alkylene, and R2 is C1-C4 alkyl.
[0038] For example, commonly used aminosilane coupling agents include aminopropyltrimethoxysilane, aminopropyltriethoxysilane, β-aminoethyl-γ-aminopropyltrimethoxysilane, β-aminoethyl-γ-aminopropyltriethoxysilane, etc., which can be directly obtained from the market.
[0039] In the above technical solution, the structure of the phosphorylcholine-containing (meth)acrylate is shown in the following formula (2):
[0040]
[0041] Wherein, R3 is selected from H or C1-C4 alkyl, R4 is one or a combination of polyethoxy and polypropoxy with a degree of polymerization of 1-10 or C1-C10 alkylene, R5, R6 and R7 are independently selected from C1-C8 alkyl, and a=1-10.
[0042] For example, the phosphorylcholine-containing (meth)acrylate can be (meth)acryloyloxyethyl phosphorylcholine (MPC), (meth)acryloyloxypropyl phosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethyl phosphate, 2-[(meth)acryloylamino]ethyl-2'-(trimethylammonio)-ethyl phosphate, 3-[(meth)acryloylamino]propyl-2'-(trimethylammonio)ethyl phosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonio)ethyl phosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 6-((meth)acryloyloxy)hexyl-2'-( 2-((meth)acryloyloxy)ethyl-2'-(triethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tripropylammonio)ethyl phosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethyl phosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)ethyl phosphate, and the like.
[0043] In the above technical solution, the structure of the alkyl acrylate is shown in the following formula (3):
[0044] CH2=C(R8)COOR9 (3)
[0045] Wherein, R8 is selected from H or C1-C4 alkyl, and R9 is selected from C1-C8 alkyl.
[0046] For example, the alkyl acrylate may be butyl acrylate, butyl methacrylate, ethyl acrylate, ethyl methacrylate, isooctyl acrylate, isooctyl methacrylate, etc. The alkyl acrylate is preferably butyl acrylate or butyl methacrylate.
[0047] In the present invention, after the acrylate copolymer and the aminosilane coupling agent undergo a ring-opening reaction, the anhydride structure forms a carboxyl group. When there are too many carboxyl groups, it may cause discomfort to the eyes. The pH can be adjusted by a buffer solution, or some or all of the carboxyl groups can be reacted and converted into other structures or relatively inert structures. In the above technical scheme, the carboxyl group generated by the ring-opening reaction product of the acrylate copolymer and the aminosilane coupling agent reacts with the aminosilane coupling agent to form an amide structure. By using the aminosilane coupling agent, the dehydration reaction of the carboxyl group and the amino group can be used to form an amide structure to achieve the blocking of the carboxyl group.
[0048] In the above technical solution, the carboxyl group generated by the ring-opening reaction product of the acrylate copolymer and the aminosilane coupling agent can also react with the amine alkyl group to form an amide structure. By using the amine alkyl group, the dehydration reaction of the carboxyl group and the amino group can be used to form an amide structure to achieve the blocking of the carboxyl group.
[0049] The structure of the aminoalkyl group is shown in the following formula (4):
[0050] NH2R 10 (4)
[0051] Where R 10 Selected from C1-C10 alkyl or C2-C10 oxygen, sulfur or nitrogen substituted alkyl.
[0052] For example, the amine alkyl group can be aminopropane, aminobutane, aminohexane, ethanolamine, propanolamine, 2-(2-aminoethoxy)ethanol, and the like.
[0053] On the other hand, the present invention provides a method for surface treatment of a corneal contact lens, which comprises using a treatment liquid containing the surface treatment agent described in any of the above technical solutions to perform surface treatment.
[0054] The raw materials for manufacturing corneal contact lenses include acrylic acid, methacrylic acid, hydroxyethyl methacrylate, N-vinyl pyrrolidone, N,N-dimethylformamide, butyl acrylate, butyl methacrylate, vinyl acetate, trifluoroethyl methacrylate, hexafluoroisopropyl methacrylate, allyl methacrylate, ethylene glycol dimethacrylate, siloxane styrene, siloxane methacrylate, silicone macromonomers, etc. Corneal contact lenses can be divided into hard, semi-hard and soft types according to hardness, but due to the raw material composition, they are easy to absorb protein during wearing. Using a treatment solution containing the surface treatment agent of the present invention to treat corneal contact lenses can improve the anti-protein adsorption performance of corneal contact lenses, and the stability is good and the performance is long-lasting.
[0055] In the above technical solution, the contact lens is pre-treated with plasma before surface treatment. The components of the contact lens are generally organic, and the surface is inert, which will affect the treatment effect of the surface treatment agent of the present invention. Plasma treatment of the contact lens can form relatively abundant hydroxyl groups, carboxyl groups, etc. on the surface of the contact lens, achieving good reaction with the alkoxysilyl groups on the structure of the surface treatment agent of the present invention.
[0056] In the above technical solution, the concentration of the surface treatment agent in the treatment liquid is 0.01-1wt%. For example, the concentration of the surface treatment agent in the treatment liquid can be any value of 0.01wt%, 0.05wt%, 0.08wt%, 0.1wt%, 0.12wt%, 0.15wt%, 0.18wt%, 0.2wt%, 0.25wt%, 0.3wt%, 0.35wt%, 0.4wt%, 0.45wt%, 0.5wt%, 0.55wt%, 0.6wt%, 0.65wt%, 0.7wt%, 0.75wt%, 0.8wt%, 0.85wt%, 0.9wt%, 0.95wt%, 1wt%, etc., without special restrictions. Further, the concentration of the surface treatment agent in the treatment liquid is 0.05-0.2wt%, which can not only achieve a better treatment effect, but also avoid cost increase.
[0057] In the above technical solution, the treatment liquid also contains a surfactant. The surfactant can play a role in cleaning the corneal contact lens. For example, the surfactant can be a nonionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, such as poloxamer 407, poloxamer 235, poloxamer 188, poloxamer 403, poloxamer 237, poloxamer 124, alkyl diaminoethyl glycine, benzalkonium chloride, benzethonium chloride, sodium dodecylbenzene sulfonate, sodium dodecyl sulfate, etc. The amount of the surfactant can be 0.01-0.5% of the amount in the care solution.
[0058] The care solution of the present invention may also contain a pH buffer (boric acid buffer, phosphate buffer, carbonate buffer, citric acid buffer, acetate buffer, etc.), sodium chloride, a moisturizer, pure water, a preservative, an antibacterial agent, etc.
[0059] The technical solution of the present invention is further described and illustrated according to various embodiments below. Unless otherwise specified, the parts described in the following embodiments are parts by weight.
[0060] Example 1-10 Preparation of surface treatment agent
[0061] Example 1
[0062] The solvent DMF was dehydrated and dried.
[0063] Add 30 parts of (meth)acryloyloxyethyl phosphorylcholine, 67 parts of butyl acrylate and 3 parts of maleic anhydride to 150 parts of DMF, stir to dissolve, add 1 part of AIBN initiator, heat to 70°C and react for 8 hours, cool to obtain a polymer solution, put the polymer solution into 2000 parts of ether for precipitation, filter and collect the precipitate, wash the precipitate twice with ether, and dry in an oven at 50°C overnight to obtain an acrylate copolymer.
[0064] Take 10 parts of acrylate copolymer and dissolve them in 40 parts of dehydrated anhydrous ethanol, add 3-aminopropyltrimethoxysilane according to the molar ratio of anhydride group to amino group of 1:1.2, stir at room temperature for 2 hours, heat to 50°C and continue to react for 2 hours, then put the solution into 500 parts of ether for precipitation, filter and collect the precipitate, wash the precipitate with ether twice, and dry it in an oven at 50°C overnight to obtain a surface treatment agent.
[0065] Example 2
[0066] The difference between this embodiment and embodiment 1 is that in embodiment 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 30 parts to 50 parts, and butyl acrylate is adjusted from 67 parts to 47 parts. The other steps remain unchanged.
[0067] Example 3
[0068] The difference between this embodiment and embodiment 1 is that in embodiment 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 30 parts to 70 parts, and butyl acrylate is adjusted from 67 parts to 27 parts. The other steps remain unchanged.
[0069] Example 4
[0070] The difference between this embodiment and embodiment 1 is that in embodiment 1, (meth)acryloyloxyethyl phosphorylcholine is adjusted from 30 parts to 85 parts, and butyl acrylate is adjusted from 67 parts to 12 parts. The other steps remain unchanged.
[0071] Example 5
[0072] The difference between this embodiment and embodiment 3 is that in embodiment 1, maleic anhydride is adjusted from 3 parts to 1 part, and butyl acrylate is adjusted from 27 parts to 29 parts. The other steps remain unchanged.
[0073] Example 6
[0074] The difference between this embodiment and embodiment 3 is that in embodiment 1, maleic anhydride is adjusted from 3 parts to 5 parts, and butyl acrylate is adjusted from 27 parts to 25 parts. The other steps remain unchanged.
[0075] Example 7
[0076] Take 10 parts of the surface treatment agent in Example 3, 2 parts of 4-n-butylamine and 0.5 parts of dicyclohexylcarbodiimide (DCC) and add them to 30 parts of DMF solvent. Stir and react at 40°C for 3 hours. The product is put into 500 parts of ether for precipitation. The precipitate is filtered and collected. The precipitate is washed twice with ether and dried in an oven at 50°C overnight to obtain a carboxyl-terminated surfactant product.
[0077] Example 8
[0078] The difference between this embodiment and embodiment 7 is that in embodiment 7, 4-n-butylamine is replaced by an equal weight of ethanolamine. The remaining steps remain unchanged.
[0079] Example 9
[0080] The difference between this embodiment and embodiment 7 is that in embodiment 7, 4-n-butylamine is replaced by an equal weight of 3-aminopropyltrimethoxysilane. The other steps remain unchanged.
[0081] Comparative Example 1
[0082] Comparative Example 1 is the acrylic acid ester copolymer in Example 3.
[0083] Comparative Example 2
[0084] The solvent DMF was dehydrated.
[0085] Add 70 parts of (meth)acryloyloxyethyl phosphorylcholine, 27 parts of butyl acrylate and 3 parts of vinyltrimethoxysilane to 100 parts of DMF, stir to dissolve, add 1 part of AIBN initiator, heat to 70°C and react for 8 hours, cool to obtain a polymer solution, put the polymer solution into 2000 parts of ether for precipitation, filter and collect the precipitate, wash the precipitate twice with ether, and dry in an oven at 50°C overnight to obtain a surface treatment agent.
[0086] Comparative Example 3
[0087] The difference between this comparative example and comparative example 2 is that in comparative example 2, vinyl trimethoxysilane is replaced by an equal weight of 3-acryloxypropyl trimethoxysilane. The remaining steps remain unchanged.
[0088] Example 10
[0089] The solvent DMAc was used for dehydration treatment.
[0090] 65 parts of (meth)acryloxypropyl phosphorylcholine, 25 parts of butyl acrylate, 8 parts of ethyl acrylate and 2 parts of maleic anhydride were added to 200 parts of DMAc, stirred to dissolve, and then 1 part of AIBN initiator was added. The temperature was raised to 70°C for reaction for 8 hours, and the temperature was lowered to obtain a polymer solution. The polymer solution was put into 4000 parts of ether for precipitation, and the precipitate was collected by filtration. The precipitate was washed twice with ether and dried in an oven at 50°C overnight to obtain an acrylate copolymer.
[0091] Take 10 parts of acrylate copolymer and dissolve them in 40 parts of DMAc, add β-aminoethyl-γ-aminopropyltrimethoxysilane according to the molar ratio of anhydride group to amino group of 1:1.5, stir at room temperature for 4 hours, and then put the solution into 500 parts of ether for precipitation. The precipitate is collected by filtration, washed with ether twice, and dried in an oven at 50°C overnight to obtain a surface treatment agent.
[0092] Embodiment 11
[0093] The difference between this example and Example 10 is that in Example 9, (meth)acryloyloxypropylphosphorylcholine is replaced by an equal weight of 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethyl phosphate. The remaining steps remain unchanged.
[0094] Comparative Example 4
[0095] The solvent DMAc was used for dehydration treatment.
[0096] Add 65 parts of (meth)acryloxypropyl phosphorylcholine, 25 parts of butyl acrylate, 8 parts of ethyl acrylate and 2 parts of 3-acryloxypropyltrimethoxysilane to 200 parts of DMAc, stir to dissolve, add 1 part of AIBN initiator, heat to 70°C and react for 8 hours, cool to obtain a polymer solution, put the polymer solution into 4000 parts of ether for precipitation, filter and collect the precipitate, wash the precipitate twice with ether, and dry it in an oven at 50°C overnight to obtain a surface treatment agent.
[0097] Contact lens surface treatment
[0098] Commercially available contact lenses are cleaned with a cleaning agent and dried before being surface treated with plasma.
[0099] The surface treatment agents obtained in Examples 1-10 and Comparative Examples 1-4 were dissolved in pure water to prepare a care solution with a concentration of 0.3wt%. If the solubility of the surface treatment agent is poor, some anhydrous ethanol can be appropriately added to promote dissolution, but the final concentration of the surface treatment agent is 0.3wt%.
[0100] The plasma-treated corneal contact lens was immersed in the above-mentioned care solution for 5 hours, taken out, washed with pure water for 3 times, and placed in a 50° C. oven to dry for 2 hours.
[0101] Evaluation method for protein adsorption resistance: The treated contact lens was immersed in 3 ml of artificial tears and placed at 37°C for 24 hours. The protein weight in the solution was quantified using the BCA method (the calibration curve was bovine serum albumin), and the amount of protein reduction in the solution was calculated as the amount of protein adsorption.
[0102] Artificial tears composition: 1.2 mg / ml lysozyme, 3.88 mg / ml albumin, 1.61 mg / ml γ-globulin, 9.00 mg / ml sodium chloride, 0.14 mg / ml potassium dihydrogen phosphate, 0.80 mg / ml disodium hydrogen phosphate heptahydrate, and the remainder is pure water.
[0103] The results are shown in Table 1. Comparative Example 5 is a completely untreated corneal contact lens, and Comparative Example 6 is a plasma-treated corneal contact lens.
[0104] Table 1
[0105]
[0106] It can be seen from the data in Table 1 that the corneal contact lens treated with the surface treatment agent of the present invention has good anti-protein adsorption performance and a very low protein adsorption amount.
[0107] According to the above method for preparing a care solution and a method for treating a contact lens, the surface treatment agent of Example 3 was used to prepare care solutions with concentrations of 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, and 0.5wt%, respectively, and the surface of the contact lens was treated. According to the above anti-protein adsorption evaluation method, the corresponding protein adsorption amounts when the surface treatment agent concentrations were 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, and 0.5wt% were 0.18mg, 0.15mg, 0.13mg, 0.12mg, and 0.10mg, respectively.
[0108] The surface treatment agents obtained in Example 3, Example 7, Example 9 and Comparative Example 3 were respectively formulated into a care solution with a concentration of 0.3wt%, and treated according to the above-mentioned contact lens treatment method. The treated contact lens was immersed in 3ml of artificial tears, left to stand at 37°C for 24 hours, taken out and immersed in a commercially available contact lens care solution (Haichang, long-lasting clean water brightening) for 6 hours, taken out, washed twice with pure water, and then immersed in artificial tears. After 30 times of protein adsorption test and cleaning care, the anti-protein adsorption performance was tested again according to the above-mentioned anti-protein adsorption evaluation method, and the protein adsorption amounts of Example 3, Example 7, Example 9 and Comparative Example 3 were measured to be 0.21mg, 0.23mg, 0.27mg and 0.74mg, respectively. Therefore, it can be seen that the surface treatment agent of the present invention is used to treat contact lenses, has good grafting stability and good durability.
[0109] As described above, the basic principles, main features and advantages of the present invention are shown and described. Those skilled in the art should understand that the present invention is not limited by the above embodiments, which are only preferred embodiments of the present invention and cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the scope of the present invention and the content of the specification should still be within the scope of the present invention. The scope of protection required by the present invention is defined by the attached claims and their equivalents.
Claims
1. A surface treatment agent, characterized in that: The surface treatment agent is a ring-opening reaction product of an acrylate copolymer and an aminosilane coupling agent, wherein the acrylate copolymer is copolymerized by the following comonomers: (A) 5-85% by weight of phosphorylcholine-containing (methyl) acrylate, (B) 10-90% by weight of alkyl acrylate, and (C) 1-5% by weight of maleic anhydride.
2. The surface treatment agent according to claim 1, characterized in that The structure of the aminosilane coupling agent is shown in the following formula (1): NH2R1Si(OR2)3(1) Among them, R1 is C2-C8 alkylene or C3-C8 oxygen, sulfur, nitrogen substituted alkylene, and R2 is C1-C4 alkyl.
3. The surface treatment agent according to claim 1, characterized in that The structure of the phosphorylcholine-containing (meth)acrylate is shown in the following formula (2): Wherein, R3 is selected from H or C1-C4 alkyl, R4 is one or a combination of polyethoxy and polypropoxy with a degree of polymerization of 1-10 or C1-C10 alkylene, R5, R6 and R7 are independently selected from C1-C8 alkyl, and a=1-10.
4. The surface treatment agent according to claim 1, characterized in that The structure of the alkyl acrylate is shown in the following formula (3): CH2=C(R8)COOR9 (3) Wherein, R8 is selected from H or C1-C4 alkyl, and R9 is selected from C1-C8 alkyl.
5. The surface treatment agent according to claim 1, characterized in that The carboxyl group generated by the ring-opening reaction product of the acrylate copolymer and the aminosilane coupling agent reacts with the aminosilane coupling agent to form an amide structure.
6. The surface treatment agent according to claim 1, characterized in that The carboxyl group generated by the ring-opening reaction product of the acrylic ester copolymer and the aminosilane coupling agent reacts with the amine alkyl group to form an amide structure. The structure of the aminoalkyl group is shown in the following formula (4): NH2R 10 (4) Where R 10 Selected from C1-C10 alkyl or C2-C10 oxygen, sulfur or nitrogen substituted alkyl.
7. A method for surface treatment of a corneal contact lens, characterized in that: The surface treatment is carried out using a treatment liquid containing the surface treatment agent according to any one of claims 1 to 6.
8. The surface treatment method of a contact lens according to claim 7, characterized in that: The contact lens is previously plasma treated prior to the surface treatment.
9. The surface treatment method of a contact lens according to claim 7, characterized in that: The concentration of the surface treatment agent in the treatment solution is 0.01-1 wt %.
10. The surface treatment method of a corneal contact lens according to claim 7, characterized in that: The treatment liquid further contains a surfactant.
